MenHibrix FDA Approval History
FDA Approved: Yes (First approved June 14, 2012)
Brand name: MenHibrix
Generic name: Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
Treatment for: Haemophilus influenzae Prophylaxis, Meningococcal Meningitis Prophylaxis
MenHibrix (Hib-MenCY-TT) is a combination vaccine for the active immunization of infants and young children 6 weeks through 18 months of age for the prevention of invasive diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib).
Development Timeline for MenHibrix
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.